Recent

% | $
Quotes you view appear here for quick access.

Sinovac Biotech Ltd. Message Board

  • svanewinvestor svanewinvestor Nov 2, 2009 5:51 PM Flag

    北京科兴再获甲流疫苗订单 将全力完成生产任务

    http://www.vos.com.cn/2009/10/28_142879.htm

    海峡之声网 2009-10-28 20:42:18



      (海峡之声记者刘新北、特约记者董梁北京报道)日前,北京科兴生物制品有限公司再次获得了国家下达的甲流疫苗订单。据悉,至09年12月12日前,该公司需完成519万剂甲型H1N1流感疫苗的生产任务。对此科兴方面表示,将全力完成甲流疫苗的生产任务。
      目前,北京市正按照知情同意、自愿、免费原则,有计划地为学生、老年人、社会公共服务人员等5类重点人群,积极接种甲型H1N1流感疫苗,11月中旬完成中小学生和社会公共服务人员的接种工作,随后启动老年人和慢性病患者的接种工作。北京科兴生物制品有限公司副总经理王楠 ,根据目前的生产任务,全部流感生产车间以及相应的辅助部门都在加班加点,依据任务的不同,个别工序甚至安排了3班24小时的工作。科兴公司将竭尽全力完成疫苗的生产任务。
      从对接种人群的监控来看,甲流疫苗的安全性完全符合标准,未出现严重的不良反应病例。王楠表示,从技术上来说,目前生产的甲流疫苗并非全新的技术,而是采用了和季节性流感疫苗一样的工艺,而季节性流感疫苗已经使用了多年,事实证明,该工艺生产出来的疫苗是安全有效的。

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Here is the English translation, using google.com translator

      (Voice of the Straits Liu's north, special correspondent reporting from Beijing Liang Dong) has, Beijing Sinovac Biotech Co., Ltd. was re-issued by a stream of national vaccine orders. It is learned that, to December 12, 2009, the company should complete the 5.19 million Influenza A H1N1 influenza vaccine production tasks. This Kexing side said it will try to complete the task of a flow of vaccine production.
      Currently, Beijing is in accordance with informed consent, voluntary, free of charge in principle, there are plans for students, seniors, social and public service personnel category 5 priority groups, active vaccination Influenza H1N1 influenza vaccine in mid-November to complete primary and secondary school and social public service personnel of the vaccination, followed by the elderly and chronically ill patients to start vaccination. Beijing Sinovac Biotech Co., Ltd. Deputy General Manager of Wang Nan, based on current production tasks, all influenza production workshop and the corresponding auxiliary branch in overtime, based on the differences in mandates, individual processes and even arranged for three classes a 24-hour work. Kexing company will make every effort to complete the vaccine production tasks.
      From the vaccinated population monitoring point of view, a stream in full compliance with the safety of the vaccine standards, no cases of severe adverse reactions. Wang Nan said that, technically, the current vaccine is not produced by a flow of new technologies, but using the same and seasonal influenza vaccine technology, while the seasonal influenza vaccine has been used for many years, it is proved that the process of production out of the vaccine is safe and effective.

    • It means SVA will endeavor to achieve supplying all the orders of A-Flu vaccine completely.

 
SVA
5.25+0.35(+7.14%)Jun 30 4:00 PMEDT